Can the HPV vaccine stop the virus in its tracks? new study aims to find out
NCT ID NCT05334706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving the 9vHPV (Gardasil-9) vaccine to women who already have HPV16 or 18 can reduce the virus's ability to infect others. Researchers will measure viral activity in cervical, anal, and oral samples before and after vaccination. The goal is to see if the vaccine's antibodies can neutralize the virus at the site of infection, potentially lowering transmission to partners.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gynaecology Unit, Bellvitge University Hospital (HUB)
RECRUITINGL'Hospitalet de Llobregat, Catalonia, 08907, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blast of argon plasma wipe out cervical precancer without surgery?
- HPV DNA test could slash cervical cancer deaths in High-Risk populations
- Could a Light-Activated cream replace surgery for cervical precancer?
- New light treatment could replace surgery for cervical precancer
- Keytruda may offer new hope for cervical precancer
- New study seeks to predict which cervical precancers will disappear without surgery